Oxazolidinone and Macrolide Programs

Multiple Candidates in Pre-clinical and Clinical Studies

Melinta Therapeutics’ early stage pipeline also includes novel compounds in established antibiotic classes in preclinical and clinical testing. The Oxazolidinone Program and Macrolide Program utilize the Company’s proprietary technology that allows for the precise targeting of binding sites within the bacterial ribosomes to improve and optimize drug properties and performance.

Radezolid: a Second-Generation Oxazolidinone


  PRODUCT/INDICATION PRE CLINICAL PHASE 1 PHASE 2 PHASE 3
Radezolid
Dermatology
PARTNER

  • QIDP: Qualified Infectious Disease Product || SPA: Special Protocol Assessment

Radezolid is a second-generation oxazolidinone; Melinta scientists analyzed the ribosomal binding region of oxazolidinones with an aim to create compounds with higher binding affinity to overcome resistance to linezolid, minimal off-target activity, a pharmacokinetic profile supporting intravenous or oral bioavailability and a broader spectrum of antimicrobial activity than is currently available in the class.

An oral formulation of radezolid was assessed in two Phase 2 clinical trials in uncomplicated skin and skin structure infections and in community acquired bacterial pneumonia. In these studies, radezolid showed encouraging clinical cure rates and activity against a number of pathogens. Additionally, radezolid was well tolerated, with the most commonly reported adverse events being gastrointestinal symptoms.

In January 2015, Melinta entered into a license agreement for the development and commercialization of radezolid in topical formulations for a variety of dermatological indications. Melinta retains the option to co-develop or fully regain rights to radezolid upon completion of specific development milestones. This innovative deal structure creates multiple potential options for realizing long-term financial return for Melinta.

Click here to visit the Radezolid Publications webpage.

Macrolide Program

  PRODUCT/INDICATION PRE CLINICAL PHASE 1 PHASE 2 PHASE 3
Macrolide Program

As with other existing classes of antibiotics, bacterial resistance is growing to the widely used macrolide class. In our Macrolide program, we have created enhanced macrolides that overcome resistance, have a broader spectrum of antimicrobial activity than current macrolides, and retain or improve the properties for an oral therapy. Currently, compounds in the Macrolide Program have the potential to treat the bacteria typically identified in skin and lung infections in the community and hospital as well as respiratory disease in the animal health arena.